These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32761892)

  • 1. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis.
    Kumar P; Siripini S; Sreedhar AS
    Cancer Rep (Hoboken); 2022 Dec; 5(12):e1261. PubMed ID: 32761892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression.
    Kumar P; Devaki B; Jonnala UK; Amere Subbarao S
    Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118728. PubMed ID: 32343987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
    Zajac M; Gomez G; Benitez J; Martínez-Delgado B
    BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
    Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
    Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
    Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
    J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
    Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
    Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism.
    Kanugovi Vijayavittal A; Amere Subbarao S
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118943. PubMed ID: 33359710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.
    Tsutsumi S; Scroggins B; Koga F; Lee MJ; Trepel J; Felts S; Carreras C; Neckers L
    Oncogene; 2008 Apr; 27(17):2478-87. PubMed ID: 17968312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMP7 Induces T-DM1 Resistance and Leads to the Poor Prognosis of Gastric Adenocarcinoma
    Li H; Xu X; Liu Y; Li S; Zhang D; Meng X; Lu L; Li Y
    Anticancer Agents Med Chem; 2018; 18(14):2010-2016. PubMed ID: 30501604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR; Tabios R; Linehan WM; Neckers L
    J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
    Ruckova E; Muller P; Nenutil R; Vojtesek B
    Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.